Carpal Tunnel Research Pioneer Joins MicroLight's Medical Advisory Board.

Business Editors/Health/Medical Writers

MISSOURI CITY, Texas--(BUSINESS WIRE)--Feb. 25, 2003

MicroLight Corporation of America announced the addition of Wayne Good, M.D., to its medical advisory board. Dr. Good coordinated the research team that pioneered laser therapy for carpal tunnel syndrome during the past 12 years in the automotive industry. "The team's efforts continue to be focused on the non-surgical laser treatment of repetitive stress injuries (R.S.I.)," said MicroLight President Mike Barbour. "We are thrilled to have him be a part of our medical advisory board."

Dr. Good is a general surgeon in private practice and on the staff of St. Joseph's Hospital in Pontiac, Mich., and medical director for a local automotive plant. He has been participating in the design and execution of a major study validating the application of MicroLight's ML830 low-level laser to treat repetitive stress injuries.

In addition to the repetitive stress injury treatment, Dr. Good is using the ML830 to treat small-joint arthritis with great success. He is also actively researching additional applications for low-level laser therapy. "I am excited that the FDA has approved the usage of the low-level laser therapy for the non-surgical treatment of carpal tunnel syndrome," said Dr. Good.

MicroLight is the only company that has received FDA clearance to market low-level laser therapy for non-surgical treatment of carpal tunnel syndrome, or CTS. CTS is the No. 1 repetitive stress injury problem in the workforce, costing the U.S. health care industry more than $10 billion annually.